ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Northwest Biotherapeutics Inc (QB)

Northwest Biotherapeutics Inc (QB) (NWBO)

0.265355
0.00
(0.00%)
Closed February 19 4:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.265355
Bid
0.2601
Ask
0.2699
Volume
-
0.00 Day's Range 0.00
0.241 52 Week Range 0.6489
Market Cap
Previous Close
0.265355
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
3,004,095
Shares Outstanding
1,297,445,623
Dividend Yield
-
PE Ratio
-3.43
Earnings Per Share (EPS)
-0.05
Revenue
1.93M
Net Profit
-64.37M

About Northwest Biotherapeutics Inc (QB)

Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company operates in the United States, the UK, Germany and Canada and is i... Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company operates in the United States, the UK, Germany and Canada and is incorporated in Delaware, USA. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Northwest Biotherapeutics Inc (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker NWBO. The last closing price for Northwest Biotherapeutics (QB) was $0.27. Over the last year, Northwest Biotherapeutics (QB) shares have traded in a share price range of $ 0.241 to $ 0.6489.

Northwest Biotherapeutics (QB) currently has 1,297,445,623 shares outstanding. The market capitalization of Northwest Biotherapeutics (QB) is $344.28 million. Northwest Biotherapeutics (QB) has a price to earnings ratio (PE ratio) of -3.43.

NWBO Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.006645-2.443014705880.2720.2720.24137692920.25140925CS
4-0.017645-6.234982332160.2830.3580.24134179920.27977136CS
120.0131555.216098334660.25220.3580.24130040950.27631093CS
26-0.094645-26.29027777780.360.39560.24125624290.28941687CS
52-0.324945-55.04743350840.59030.64890.24121911900.35677232CS
156-0.719645-73.06040609140.9852.050.24122176070.64125051CS
2600.10185562.29663608560.16352.540.00524873910.81843347CS

NWBO - Frequently Asked Questions (FAQ)

What is the current Northwest Biotherapeutics (QB) share price?
The current share price of Northwest Biotherapeutics (QB) is $ 0.265355
How many Northwest Biotherapeutics (QB) shares are in issue?
Northwest Biotherapeutics (QB) has 1,297,445,623 shares in issue
What is the market cap of Northwest Biotherapeutics (QB)?
The market capitalisation of Northwest Biotherapeutics (QB) is USD 344.28M
What is the 1 year trading range for Northwest Biotherapeutics (QB) share price?
Northwest Biotherapeutics (QB) has traded in the range of $ 0.241 to $ 0.6489 during the past year
What is the PE ratio of Northwest Biotherapeutics (QB)?
The price to earnings ratio of Northwest Biotherapeutics (QB) is -3.43
What is the cash to sales ratio of Northwest Biotherapeutics (QB)?
The cash to sales ratio of Northwest Biotherapeutics (QB) is 113.33
What is the reporting currency for Northwest Biotherapeutics (QB)?
Northwest Biotherapeutics (QB) reports financial results in USD
What is the latest annual turnover for Northwest Biotherapeutics (QB)?
The latest annual turnover of Northwest Biotherapeutics (QB) is USD 1.93M
What is the latest annual profit for Northwest Biotherapeutics (QB)?
The latest annual profit of Northwest Biotherapeutics (QB) is USD -64.37M
What is the registered address of Northwest Biotherapeutics (QB)?
The registered address for Northwest Biotherapeutics (QB) is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
Which industry sector does Northwest Biotherapeutics (QB) operate in?
Northwest Biotherapeutics (QB) operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AABVFAberdeen International Inc (PK)
$ 0.0269
(0.00%)
0
AABKFAareal Bank AG (CE)
$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
$ 0.02625
(0.00%)
0
AAALYAareal Bank AG (PK)
$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
$ 0.55
(0.00%)
0
AABVFAberdeen International Inc (PK)
$ 0.0269
(0.00%)
0
AABKFAareal Bank AG (CE)
$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
$ 0.02625
(0.00%)
0
AAALYAareal Bank AG (PK)
$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
$ 0.55
(0.00%)
0
NTDOYNintendo Co Ltd (PK)
$ 18.90
(0.00%)
4.15M
DTEGYDeutsche Telekom AG (QX)
$ 36.08
(0.00%)
2M
LNVGYLenovo Group Ltd (PK)
$ 31.85
(0.00%)
1.36M
RSHGYResona Holdings Inc (PK)
$ 16.42
(0.00%)
942.29k
FANUYFanuc Corporation (PK)
$ 14.61
(0.00%)
587k

NWBO Discussion

View Posts
learningcurve2020 learningcurve2020 25 minutes ago
You can read all about it on the NWBO website. 🙄🙄🙄
👍️0
FeMike FeMike 25 minutes ago
Man I hope yesterday's strong close carries into today for some reason.

Sick of these mini-runs just petering out and going straight back into the downtrend. Would be nice to stop the bleeding at list for a little while.
👍 3 🚽 1 🪠 1
learningcurve2020 learningcurve2020 28 minutes ago
Seems to me there are only two possibilities at this point; 1. MHRA is waiting for other trial data but investors aren’t being told. 2. The application is being passed from desk to desk like a hot potato until it eventually disappears, but investors aren’t being told.
👍️0
learningcurve2020 learningcurve2020 34 minutes ago
“Referencing Northwest”…How so? Seems to me Cognate and Advent now have more competition. And, btw, you see he says Roswell Institute can do NG, T, and DC’s, so likely the same with Advent. So why isn’t revenue showing up from Sawston? 🤷‍♀️
👍️0
dmb2 dmb2 1 hour ago
Absolutely true, new technologies that an RA is not familiar with and has not previously reviewed, inspected and approved require more explanation and data. If FW is not included in the MAA then the basic processing they utilized will not be new to the MHRA, so little need for shareholders to focus on it. Remember compassionate use was approved so the processing is understood and acceptable to the regulators.
When FW is submitted it will require more explanation and data along with what they have already communicated to MHRA about the technology, which they undoubtedly have already broken ground with info about what they are doing, a benefit of being a PIM and an orphan drug.

GLTA
👍️ 3
dmb2 dmb2 1 hour ago
The MAA has apparently been acceptable on all fronts to date to get to the last stage of review and approval. That typically simply means the clinical review has passed, the CMC review has passed and the final steps are inspections and then labeling negotiations. It is never impossible but highly unlikely that there is still a critical clinical review question still not addressed unless a new question popped up during an inspection, which would tend to be a procedural type of compliance observation.
Given the elapsed time between the conduct of the clinical trial and current MAA review it would not be hard to fathom a procedural question as systems, procedures and personnel evolve. The answers would expectedly be forthcoming, though may take a little time to re-create some historical explanations if they had to go back to the start of the trial to explain.
There may be a little complexity in the labeling area also as both n and rGBM have been filed for and some commentary has been around about earlier stage gliomas as well.
I always like to remind myself of how BP's handle all RA questions with teams of experts while a company like NWBO is typically less endowed with such resources, which can also take a little more time to gather responses.
All in all getting to this stage is very positive and we know the mfg site has performed well in inspections, placing NWBO in good position here.

GLTA
👍️ 11 😁 2 🙏 3 🤔 1 🫰 1 ⛽️ 1
Locknload56 Locknload56 3 hours ago
We are ALL Roswell !
👍 1 ⛽️ 1
FeMike FeMike 3 hours ago
Fair enough, thanks Doc.
🚽 1 🪠 1
DocLee DocLee 4 hours ago
FeMike, there was no argument. You made a statement which I found to be very pessimistic and did not trust. As this discussion board is infested with peddlers of pessimistic statements which are factually unfounded, I asked you for the facts on which your pessimism was based. You provided those facts, I sought NWBO's comments on those facts and NWBO did not dismiss them as incorrect. Accordingly, I accepted that what you said is factually correct. How your scenario plays out in the coming weeks/months is open to debate.
However, I did not "claim that reimbursement will be fully negotiated upon approval". I said that whilst the MHRA were deliberating part of my expectations were that Management would be working with NICE to agree an acceptable price for DCVax-L. That was not a prediction but was an expectation and when the MAA was granted : "if it transpires that in the 26 months between November 2022 when the phase 3 trial results were first published and now management has not been seriously addressing the price of DCVax-L with NICE, my faith in them will be destroyed. Clearly, I must await the MHRA's decision before I can learn just what Management has been doing (or not doing) in that 26 month period and I presume that is why I was advised by NWBO to "keep the faith".
As to NWBO cutting corners on the NICE approval, that has never been suggested. What has been alluded to is that NWBO has been in discussion with NICE for years. I'm sure that this has been useful for both sides so that when negotiations are fully under way (if the first steps have not already been taken unofficially) all the groundwork will have been done. As to NICE, I am sure that without prompting they can see the importance of DCVax-L so will (I hope) pull out all the stops to get a quick and mutually fair agreement so that 25-30 patients with GBM per week in the UK can receive potentially life-saving treatment where none currently exists.
👍️ 11
DocLee DocLee 5 hours ago
Thanks, FeMike, for your DD and I just hope (but not holding my breath) that the NICE bureaucrats and their advisors don't dawdle in their internal discussions once they receive NWBO's evidence package - if they've not already received it.
If the latter is the case, I would like to know why NWBO has not sent it already, especially when they decided on the timing about a year ago. After all, after a 10-year phase 3 trial and over a year of analysis of the results just what new evidence might NWBO think could appear in the time between the ASM and the granting of the MAA that might materially affect their calculations on the projected unit price?
👍 2
DocLee DocLee 5 hours ago
Biosect, I understand what you are saying "We know they [NWBO] requested to be in the expedited process, but it does not seem as though they are.." but it would be somewhat peculiar for NICE not to be in talks with NWBO over the likely price of DCVax-L especially when (as most unprejudiced commentators all agree) ) the MHRA are imminently likely to be giving its blessing to DCVax-L. After all, NICE and NWBO have been in talks for years so why stop now, just when when an agreed price is the last piece of the jigsaw for a treatment which is clearly needed and is the first advance in 30 years of the treatment of a near universal killer.

I doubt that NICE protocols are so inflexible that the process can only run like a commuter train stopping at every intermediate station. Instead, when the need is there the protocols must/should/could/ought to be be adjustable so that the process becomes an express train with no stopping from beginning to end.... and the need for a speedy resolution of the negotiations is definitely there.
👍 3
pgsd pgsd 7 hours ago
Definitely interesting as the trial was recently updated, showing 'not recruiting' but it appears to still be active.

Updated:2024-11-27 01:06:13
Trial ID:2024-516613-21-00
Trial Phase:Phase I and Phase II (Integrated)

'On the EU Clinical Trials Register, a "not recruiting" status means that a clinical trial is currently not actively seeking new participants, although it may still be ongoing with enrolled participants receiving treatment or undergoing assessments; essentially, the trial is not actively enrolling new individuals at this time'

https://clinicaltrials.eu/trial/study-on-murcidencel-for-children-adolescents-and-young-adults-with-high-risk-progressive-or-recurrent-metastatic-tumors/

•Timeline Consistency:

The "new" Murcidencel trial has a start date of 2015 , which coincides with the completion of the DCVax-L Phase III trial . This suggests that the trial might have been conducted using DCVax-L, but the official INN "Murcidencel" was assigned later.
https://x.com/peter_brit/status/1892053443973612020

👍️ 10 🚀 1
manibiotech manibiotech 8 hours ago
They built their own academic facility per article
Feel free to email them and let us know if you find out anything different 
👍️0
Bright Boy Bright Boy 9 hours ago
Great post !! The Roswrell Parks deal is worth multiple millions in clinical trial expense and time, not to mention the multiple billions, when the trials are successful. All of the medical community knows this as well as most institutional players, but Griffin et al managed to mask the value and destroy momentum by painting the screen red.Law enforcement probably knows this as well.

Cheers,

BB
👍️ 19 💯 8 🔥 2 🙏 3 🚀 1
XMaster2023 XMaster2023 9 hours ago
Greater than yours….
By far.
👍️ 1
XMaster2023 XMaster2023 9 hours ago
And you don’t see any association with NWBO?
👍️0
AAPL31415926 AAPL31415926 10 hours ago
Northwest Biotherapeutics (NWBO) acquired an exclusive license for a portfolio of dendritic cell technologies and intellectual property (IP) from Roswell Park Comprehensive Cancer Center. This deal, finalized on June 12, 2024, includes:

Five new patent families filed in 2023, which have their full potential patent life ahead of them.
Enhanced versions of dendritic cells (DCs) and DC-based therapies.
Conditioning regimens designed to enhance patient responses.
Approaches to reprogram the tumor microenvironment to boost immune therapies and help overcome resistance to checkpoint inhibitors.

These technologies are already in Phase 2 clinical trials for two different cancers, with a third trial pending. The license complements NWBO's existing portfolio, which was also developed by Dr. Pawel Kalinski at Roswell Park. The acquisition was aimed at enhancing NWBO's capabilities in developing personalized immune therapies for solid tumor cancers.
🏆️ 1 👍️ 21 💯 9
NotSure2 NotSure2 10 hours ago
Mani, wait for Dstock to find the correlation, I believe he used his post for today. Pretty sure he'll find something.

(maybe a new McDonnald has open its door 2-3 minute walk from the Roswell academic center, which would clearly corrolate with NWBO future employees being able to take a quick lunch. Or maybe there is a new bus stop near by, which clearly indicate the city anticipation to future NWBO workers).

Whatever it is, Dstock will be able to find the correlation, just a little more patience is needed.
👍 5 👙 1 👚 1 👿 1 💀 1 😂 2 🤣 2
norisknorewards norisknorewards 11 hours ago
In your doomsday nafariously depressing scenerio, at least I can see the silver lining...

The end of seeing your daily bitsching as I will keep on trucking on.

But if I felt there was an inkling of reason to be concerned here, I'd have sold a long while ago. The news to me seems to keep getting better and better.
👍️ 3
hankmanhub hankmanhub 11 hours ago
So what exactly did NWBO acquire from Roswell, and what did they not get?
👍️0
manibiotech manibiotech 11 hours ago
This article clearly says it's Roswell academic center .
So at least I  don't see any correlation with NWBO
👍️ 2 👿 1 💀 1
hankmanhub hankmanhub 11 hours ago
based on the deal between NWBO and Roswell park
👍️0
starric starric 11 hours ago
Oh ok I see. Thnx!

https://clinicaltrials.eu/inn/murcidencel/




👍 2
flipper44 flipper44 11 hours ago
That is correct.
✅️ 1
SkyLimit2022 SkyLimit2022 12 hours ago
suit,



I’m not an expert on this topic, but I believe that a company applying to commercialize a novel cell-based technology in the U.S. market needs to include a robust section in its BLA application about…

👍 9 ✔️ 5
manibiotech manibiotech 13 hours ago
I will be happy if it stays above .30 for time being 
👍️ 1
Lykiri Lykiri 13 hours ago
I think this is the study: COMBINED ANTITUMOR THERAPY WITH EX VIVO MANIPULATED DENDRITIC CELLS PRODUCING INTERLEUKIN-12 IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH PROGRESSIVE, RECURRENT, OR PRIMARILY METASTATIC HIGH-RISK TUMORS.

https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003388-39/CZ

It appears that the name murcidencel was initially used but later removed to avoid confusion with DCVax-L.
👍 20 💯 6
DavidW2 DavidW2 13 hours ago
$1T MC? LOL. I am very happy if it can reach 50 B MC, by that time, I hope I am still alive to enjoy the profit.
👍️ 8
jtaylor042 jtaylor042 13 hours ago
$1T MC, in what would be the shortest time for any company to do it. My reaction was rude, and it should not have been.

I would happily accept my skepticism turning into a plate of crow in this instance.
👍️0
froggmister froggmister 14 hours ago
Because there is a possibility.
Of course there's a possibility. It's possible that meteor heading our way will not only hit us but will hit a nuclear power plant. But what are THE ODDS that the MRHA will reject a treatment that:
1. Was featured in JAMA with the top neurologists in the world signing off on survival efficacy
2. Approved the Pediatric trial with contemporaneous controls
3. With a benign safety profile
4. For a cancer indications (both nGBM and rGBM) which have no current good options
5. It went before the CHM in July
6. With the only reasonable argument for rejection being the trial design "confounding" the results, months after the CHM (where that issue might come up) the MHRA still saw fit to use considerable resources to send inspectors around the world to $NWBO trial sites.

While it's frustrating, it's not crazy that a treatment with a complex trial and a complex manufacturing profile would take longer than, say, an already-approved-elsewhere skin eczema treatment. To think it will be rejected outright takes some logic ninja.
👍️ 28 💯 14 😁 1 🚀 2
manibiotech manibiotech 14 hours ago
https://oncdata.com/roswell-park-gmp-engineering-and-cell-manufacturing-facility/


Here is the full article referenced in that video 
Video mentions CAR-t, TCR and dendritic cell vaccines . Not sure how you conclude they are NWBO clean rooms ?
👿 1 💀 1
manibiotech manibiotech 14 hours ago
On you tube says it was uploaded 4 days ago
👍️0
hankmanhub hankmanhub 14 hours ago
Does NWBO now own the 20 clean rooms at Roswell that are spoke of in this video clip? Can you date when this video clip was made?
👍️0
NotSure2 NotSure2 15 hours ago
Havent seen the trial (no idea of which trial you are talking about and/or why you are asking me).

Its Not sure2 btw, Not sure was alrdy taken, I do not believe that username follow NWBO.
😂 1 🤣 1
theorysuit theorysuit 15 hours ago
Not sure but have you seen the trial? It is a monstrousity...wonder why they didn't apply to the FDA first?
👍️ 1 👿 1 💀 2 🚽 1
martyDg martyDg 15 hours ago
Duh! What do you think? Because there is a possibility. There’s no such thing as “de-risk,” according to cult long. You’re gullible if you believe that. There’s no such thing as 100% approval. Even in a soap advertisement, you can only kill 99.9% of germs, and that remaining 0.1% can still harm you.
👍️ 2 👿 1 💀 2 🚽 1
martyDg martyDg 15 hours ago
If the MHRA rejects it, that will be the final nail in the coffin. LP will finally be unable to dangle any more carrots in front of us. Only the gullible will still believe after this. 
👍️ 1 👿 1 💀 2 🚽 2
DavidW2 DavidW2 15 hours ago
What is Xmaster MC prediction?
👿 1 💀 2 🚽 1
Jackxkr Jackxkr 15 hours ago
Y is it getting rejected, on what premise?
👿 1 💀 1
theorysuit theorysuit 15 hours ago
if this gets rejected, it is toast with zero cash and big time debt.

but yeah the pumpers will say de-risked and breakthrough cancer therapy.....cough cough yeah right.
👍️ 3 👿 1 💀 1
KRISGO KRISGO 16 hours ago
If this belongs to NWBO, why wouldn't they notify investors before it begins? Or are they waiting for approval to use PR to target the shorts? Or is the news source unreliable and untrustworthy?

In this study, a new treatment is being tested for children, adolescents, and young adults with high-risk tumors that are either getting worse, have come back, or have spread to other parts of the body. These types of tumors are serious and can be difficult to treat with standard methods. The treatment being studied is a special type of vaccine called the autologous dendritic cell vaccine. This vaccine is made from the patient’s own cells and is designed to help the immune system fight the cancer. The vaccine works by using dendritic cells, which are a type of immune cell, to produce a substance called interleukin-12 that can boost the body’s natural defenses against cancer.
👍️0
RobotDroid RobotDroid 16 hours ago
Accelerated is a word Linda has zero knowledge of. Inept mute worlds worst ceo ever.
👍️ 2 👿 1 💀 1
RobotDroid RobotDroid 16 hours ago
Forever.
👍️ 1 👿 1 💀 1
RobotDroid RobotDroid 16 hours ago
As you are on most intelligent longs list.
👍️ 1 👿 1 💀 1
jtaylor042 jtaylor042 16 hours ago
Fair enough. I hope I am right in this regard and that I am wrong on your market cap predictions.

Best.
👍️0
exwannabe exwannabe 17 hours ago
So a P1/P2 trial of Murcidencel being run in Czechia by some 3rd party is listed iin.climnicatrials.eu (not Eudora,).

Weird.

Maybe Advent is expanding? First Brazil, now Czechia/.
👍️0
biosectinvestor biosectinvestor 17 hours ago
Look, the application was submitted and you have no basis, whatsoever to say one way or the other, how they have responded to regulators, whether it was sufficient or not is speedy or not. Everything you post on the topic is garbage speculation and given your predisposition, not particularly relevant or appropriate to rely upon. 
👍 8
JTORENCE JTORENCE 17 hours ago
psych7 Buyers Galore?? Buy: 1,790,145 ----Sell: 902,548
Go back to sleep jerk.
👿 1 💀 1 🚽 1
martyDg martyDg 17 hours ago
That's not true? Lol. Where have you been this whole time? In a cave? Management is on the next level of slow. That's how they earned the title "Slowpokes". Anyway, you believe what you want to believe. I'm not going to argue with you.
👍️ 2 👿 1 💀 2 🚽 1
manibiotech manibiotech 17 hours ago
Common Doc this has happened innumerable times . 2 cent gain on average to below average volume ... really!!. Unless rise continues every day for several days , it's not convincing . Didn't we enter home stretch in Aug , which was SOS prediction also I guess , amongst many other times . 
👍️ 1 👿 1 💀 1

Your Recent History

Delayed Upgrade Clock